<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02516605</url>
  </required_header>
  <id_info>
    <org_study_id>CLJN452X2201</org_study_id>
    <secondary_id>2015-001590-41</secondary_id>
    <nct_id>NCT02516605</nct_id>
  </id_info>
  <brief_title>A Multi-part, Double Blind Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in PBC Patients</brief_title>
  <official_title>A Multi-part, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Efficacy of Tropifexor (LJN452) in Patients With Primary Biliary Cholangitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-part study to assess safety, tolerability and efficacy of tropifexor (LJN452) in
      patients with primary biliary cholangitis
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 9, 2015</start_date>
  <completion_date type="Anticipated">February 18, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 18, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in cholestatic markers from baseline</measure>
    <time_frame>Baseline, Part 1 at 28 Days</time_frame>
    <description>Evaluate the change in cholestatic markers following administration of LJN452</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with adverse events, serious adverse events and death</measure>
    <time_frame>end of study 12 weeks</time_frame>
    <description>Determine safety and tolerability of LJN452</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in cholestatic markers from baseline</measure>
    <time_frame>Baseline, Part 2 at 12 weeks</time_frame>
    <description>Evaluate the change in cholestatic markers following administration of LJN452</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in disease specific quality of life</measure>
    <time_frame>Baseline, Part 1: 28 days, Part 2: 12 weeks</time_frame>
    <description>Evaluate change in quality of life using PBC-40 PRO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in itch as determined by the itch domain in the PBC-40</measure>
    <time_frame>Baseline, Part 1: 28 days, Part 2: 12 weeks</time_frame>
    <description>Evaluate the change in itch using the itch domain in the PBC-40</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in itch as determined by 10mm VAS</measure>
    <time_frame>Baseline, Part 1: 28 days, Part 2: 12 weeks</time_frame>
    <description>Evaluate the change in itch from baseline with a 10 mm VAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Area under the plasma concentration-time profile (AUCtau)</measure>
    <time_frame>Day 1, Day 28</time_frame>
    <description>Evalaute AUCtau</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Maximum plasma concentration of LJN452 (Cmax)</measure>
    <time_frame>Baseline, 28 days</time_frame>
    <description>Evaluate Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum plasma concentration of LJN452 (Cmin)</measure>
    <time_frame>Baseline, Part 1: 28 days, Part 2: 12 weeks</time_frame>
    <description>Evaluate Cmin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average steady state plasma concentration following multiple doses of LJN452 (Cav,ss)</measure>
    <time_frame>Baseline, Part 1: 28 days, Part 2: 12 weeks</time_frame>
    <description>Evaluate Cav,ss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Time to reach maximum concentration after durg administration (Tmax)</measure>
    <time_frame>Day 1, Day 28</time_frame>
    <description>Evalute Tmax</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Part 2: determine the dose response relationship of LJN452 on ALP</measure>
    <time_frame>12 weeks</time_frame>
    <description>To determine the dose response relationship of LJN452 on ALP in patients with PBC following 12 weeks of treatment</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">163</enrollment>
  <condition>Primary Biliary Cholangitis</condition>
  <arm_group>
    <arm_group_label>LJN452</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 1: LJN452</intervention_name>
    <description>LJN452 capsules administered once daily for 28 days</description>
    <arm_group_label>LJN452</arm_group_label>
    <other_name>tropifexor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 1: Placebo</intervention_name>
    <description>Matching placebo capsules administered once daily for 28 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 2: LJN452 Dose level 1</intervention_name>
    <description>LJN452 capsules administered once a day for 12 weeks</description>
    <arm_group_label>LJN452</arm_group_label>
    <other_name>tropifexor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 2: Placebo</intervention_name>
    <description>Matching placebo to LJN452 administered once a day for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 2: LJN452 Dose level 2</intervention_name>
    <description>LJN452</description>
    <arm_group_label>LJN452</arm_group_label>
    <other_name>tropifexor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of PBC as demonstrated by the presence of ≥ 2 of the following 3 diagnostic
             criteria:

          -  History of Alkaline Phosphatase elevated above upper limit of normal for at least 6
             months

          -  Positive anti-mitochondrial antibodies (AMA) titer or if AMA negative or in low titer
             (&lt;1:80) PBC specific antibodies (anti- GP210 and/or anti-SP100 and/or antibodies
             against the major M2 components (PDC-E2, 2-oxo-glutaric acid dehydrogenase complex)

          -  Previous liver biopsy consistent with PBC

          -  At least 1 of the following markers of disease severity:

          -  ALP ≥ 1.67× upper limit of normal (ULN)

          -  Total bilirubin &gt; ULN but &lt; 1.5× ULN In addition, patients must meet the following
             biochemical criteria at enrollment

               -  ALT or AST ≤ 5 × ULN

               -  Total bilirubin ≤ 1.5 × ULN

               -  INR ≤ ULN

          -  Subjects must weigh at least 40 kg to participate in the study, and must have a body
             mass index (BMI) within the range of 18 - 40 kg/m^2. BMI = Body weight (kg) / [Height
             (m)]^2.

          -  Able to communicate well with the investigator, to understand and comply with the
             requirements of the study.

        Exclusion Criteria:

          -  Women of child-bearing potential, defined as all women physiologically capable of
             becoming pregnant, unless they are using highly effective methods of contraception
             during dosing and for 30 days following end of treatment.

          -  History or presence of other concomitant liver diseases

          -  Cirrhosis with complications, including history or presence of:

               -  Variceal bleed

               -  Uncontrolled ascites

               -  Encephalopathy

               -  Spontaneous bacterial peritonitis

          -  Significant hepatic impairment as defined by Child-Pugh classification of B or C,
             history of liver transplantation, current placement on a liver transplant list or
             current Model for End Stage Liver Disease (MELD) score ≥15.

          -  History of conditions that may cause increases in ALP (e.g., Paget's disease).

          -  Use of other investigational drugs at the time of enrollment, or within 5 half-lives
             of enrollment

          -  Elevated liver function tests at screening defined as follows:

               -  potential Hy's Law case (defined as ALT or AST &gt; 3 × ULN and TBL &gt; 2 × ULN
                  without notable increase in ALP to &gt; 2 × ULN) or

               -  ALT or AST &gt; 3 × ULN combined with INR &gt; 1.5.

               -  Total bilirubin &gt; ULN combined with albumin outside of the normal range.

          -  Currently taking obeticholic acid or have taken obeticholic acid within 30 days of
             Randomization.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>Novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rialto</city>
        <state>California</state>
        <zip>92377</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Munchen</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wurzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lodz</city>
        <zip>91-347</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Myslowice</city>
        <zip>41-400</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warsaw</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-449</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Samara</city>
        <zip>443011</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hull</city>
        <zip>HU3 2JZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>NW3 2PF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2015</study_first_submitted>
  <study_first_submitted_qc>August 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2015</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary Biliary Cirrhosis, PBC</keyword>
  <keyword>Primary Biliary Cholangitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

